Procalcitonin has long been used as a biomarker for the detection of community-acquired pneumonia and Prof Molnár advocates its use as a biomarker for detecting bacterial infections in COVID-19 patients. High PCT levels are directly correlated to bacterial, as opposed to viral, pneumonia. However, Prof Molnár is quick to point out that a significant overlap exists between patients with viral pneumonia and those with bacterial pneumonia, even when correcting for heightened PCT levels. He therefore concludes that PCT is best used as a biomarker to indicate the increased possibility of bacterial pneumonia.
WATCH THE VIDEO HERE:
https://www.youtube.com/watch?v=yFqolCuD4pw&list=PLGlvFEwL2wDF08kN8eM2Cr5m7C8jybOCk
